Literature DB >> 22717240

Synthesis and anticonvulsant activity of new N-Mannich bases derived from 3-(2-fluorophenyl)- and 3-(2-bromophenyl)-pyrrolidine-2,5-diones. Part II.

Jolanta Obniska1, Sabina Rzepka, Krzysztof Kamiński.   

Abstract

Synthesis and anticonvulsant activity of new N-Mannich bases of 3-(2-fluorophenyl)- and 3-(2-bromophenyl)-pyrrolidine-2,5-diones have been described. Initial anticonvulsant screening was performed in mice after intraperitoneal administration in the maximal electroshock seizure test (MES) and subcutaneous pentylenetetrazole seizures test (scPTZ). The neurotoxicity was determined applying the rotarod test. The in vivo results in mice showed that majority of compounds were effective in the MES test. Only seven molecules showed protection in the scPTZ test. The quantitative evaluation in the MES seizures after oral administration into rats showed that the most active were 1-[{4-(4-fluorophenyl)-piperazin-1-yl}-methyl]-3-(2-bromophenyl)-pyrrolidine-2,5-dione (14) with ED(50) of 7.4mg/kg and 1-[{4-(3-bromophenyl)-piperazin-1-yl}-methyl]-3-(2-bromophenyl)-pyrrolidine-2,5-dione (16) with ED(50) of 26.4mg/kg. These molecules were more potent and also less neurotoxic than phenytoin which was used as reference antiepileptic drug.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717240     DOI: 10.1016/j.bmc.2012.05.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

Review 1.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

2.  Pyrrolidine-2,5-dione.

Authors:  Min Yu; Xing Huang; Feng Gao
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-08-23

3.  1-[2-(3-Meth-oxy-phen-yl)eth-yl]pyrroli-dine-2,5-dione.

Authors:  Zeenat Fatima; Jayaraman Selvakumar; Thothadri Srinivasan; Devadasan Velmurugan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.